孕妇和儿童拉沙热疾病负担及预防选择
本文综述文献评估新生儿、儿童和孕妇中拉沙热的流行与影响及疫苗开发意义。儿童临床特征与成人相似,16项儿科研究病死率6%至63%,两项新生儿研究为66.7%和75.0%,孕妇系统综述病死率33.73%。目前四项拉沙病毒疫苗临床试验中仅一项招募≥18月龄儿童且排除孕妇和哺乳期妇女。
要点
- 儿童拉沙热临床特征与成人相似,出血等并发症常见。
- 16项儿科研究病死率6%至63%,两项新生儿研究为66.7%和75.0%。
- 孕妇系统综述病死率33.73%,胎儿不良结局包括流产、死胎和宫内死亡。
核心结论
- 拉沙热显著影响新生儿、儿童和孕妇,开发安全有效的单剂疫苗对这些高危人群至关重要。
- 必须将孕妇、哺乳期妇女和幼儿纳入具备稳健安全性监测和风险缓解措施的临床试验。
- 投资于针对特定知识缺口的综合策略对保护拉沙病毒流行区这些特定人群的健康至关重要。
研究设计与样本
- 本文为文献综述,回顾现有拉沙热文献以评估其在新生儿、儿童和孕妇中的流行与影响及对疫苗开发的意义。
- 纳入16项儿科研究、2项新生儿研究和1项孕妇研究系统综述。
- 目前有四项评估拉沙病毒疫苗的临床试验,仅一项招募≥18月龄儿童且排除孕妇和哺乳期妇女。
主要发现
- 儿童临床特征与成人相似,并发症包括出血。
- 意识状态改变、全身水肿(肿胀婴儿综合征)、出血和尿量少是死亡危险因素。
- 16项儿科研究病死率范围为6%至63%,两项新生儿研究病死率分别为66.7%和75.0%。
- 孕妇系统综述病死率33.73%。
- 胎儿不良结局包括流产、死胎和与母亲死亡相关的宫内死亡。
关键数值与推荐
- 16项儿科研究病死率范围为6%至63%。
- 两项新生儿研究病死率分别为66.7%和75.0%。
- 孕妇系统综述病死率33.73%。
- 四项拉沙病毒疫苗临床试验中仅一项招募≥18月龄儿童,且排除孕妇和哺乳期妇女。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 支持拉沙热疾病负担的数据稀疏。
- 缺乏关于拉沙热对新生儿、儿童和孕妇影响的全面的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lassa fever is a serious epidemic viral disease in West Africa affecting an estimated 2 million people annually with about 5000-10,000 deaths, although supporting data is sparse. Lassa fever significantly affects neonates, children, and pregnant women, however, comprehensive data on its impact in these populations are lacking. We reviewed the available literature on Lassa fever to assess its prevalence and impact in these populations and implications for vaccine development. Clinical features in children were similar to those observed in adults, with complications such as bleeding. Altered mental status, anasarca (swollen baby syndrome), bleeding, and poor urine output were risk factors for death. The case fatality rate (CFR) in 16 paediatric studies ranged from 6 % to 63 % and was 66.7 % and 75.0 % in two neonatal studies. In a systematic review of studies on pregnant women the CFR was 33.73 %. The adverse foetal outcomes included miscarriage, stillbirth, and intrauterine death associated with maternal death. Since Lassa fever significantly affects neonates, children, and pregnant women, developing a safe and effective, single-dose vaccine for these high-risk populations is vital. Currently, there are four clinical trials assessing Lassa virus vaccines. Only one of these trials is enrolling children aged ≥18 months, and exclude pregnant and breast-feeding women. It is essential that pregnant and breast-feeding women and young children are included in clinical trials that incorporate robust safety surveillance and risk mitigation measures. In our review, potential approaches to address the specific gaps in the areas of diagnosis, management, and prevention of Lassa fever in these specific populations, such as disease surveillance systems and vaccine development, were identified. A comprehensive strategy with investment focused on addressing specific knowledge gaps will be essential in protecting the health of these specific populations in Lassa virus endemic regions.
引用
- Chaudhary M, Cutland CL, Bonet M, et al. Burden of Lassa fever disease in pregnant women and children and options for prevention. Vaccine. 2024. PMID: 39488189. doi:10.1016/j.vaccine.2024.126479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。